Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dellorusso covers the Healthcare sector, focusing on stocks such as Upstream Bio, Inc., Soleno Therapeutics, and Crinetics Pharmaceuticals. According to TipRanks, Dellorusso has an average return of -3.7% and a 57.14% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Upstream Bio, Inc. with a $45.00 average price target.
Based on Upstream Bio, Inc.’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.03 million and a GAAP net loss of $40.59 million. In comparison, last year the company earned a revenue of $566 thousand and had a GAAP net loss of $27.27 million
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UPB in relation to earlier this year. Most recently, in March 2026, Michael Gray, the CFO and COO of UPB sold 852.00 shares for a total of $7,915.08.
